Skip to content

Internet Buzz on Sarepta Therapeutics’ Orphan Drug Eteplirsen

January 26, 2013

Two weeks after Sarepta Therapeutics’ January 2013 presentation at the J.P. Morgan Healthcare Conference, its shares increased 14% on Friday (01.25.13), due to an analyst’s positive review of the company. Edward Nash, an analyst at Cowen & Co., gives Sarepta Therapeutics’ shares an “Outperform Rating” due to its antiviral drug pipeline, technology, and orphan drug Eteplirsen.  The analyst believes that Eteplirsen, for the treatment of Duchenne Muscular Dystrophy (DMD), will be approved of in 2016, with a forecast of $263 million US sales that year.

Here is the Internet Buzz on Friday’s stock rising :

*** 1) Investment Analyst Video on Sarepta Therapeutics “Sarepta Adds Another Supporter”

*** 2) January 25, 2013 article titled, “Duchenne Muscular Dystrophy Drug Could Unlock Huge Potential For This Pharmaceutical”

3) January 25, 2013 article titled, “Sarepta Therapeutics rises on analyst rating”

4) January 25, 2013 article titled, “Why Sarepta Therapeutics Shares Popped”

5) January 25, 2013 article titled, “Cowen Assumes Coverage on Sarepta Therapeutic”.


1) Plans to ask for a meeting with the FDA for scheduling a meeting for the 1st Quarter of 2013 to discuss asking for Accelerated Approval for Eteplirsen and to also discuss a Phase III clinical trial for Eteplirsen

2) Investors probably will not be hearing about the results of the FDA meeting until about March – April 2013

3) 15th Annual TIDES (Oligonucleotide & Peptide Therapeutics From Research through Commercialization) Meeting, May 12 – 15, 2013. Jayant Aphale, Senior Vice President, Technical Operations at Sarepta Therapeutics, will give a Presentation titled, “Eteplirsen: One Small Step for Sarepta, One Giant Leap for DMD Treatment” at 4:30 – 5:00 PM, May 13, 2013, as part of a Session titled, “Üpdates on Commercialization of Therapeutic Candidates”.  The description from the meeting brochure reads :

Recent Phase II clinical data indicates Eteplirsen assists in significant slowdown of the fatal disease, Duchenne Muscular Dystrophy (DMD) in young boys as evident by significant increase in Dystrophin levels and the 6MWT results. Currently there is no therapy available for treating DMD. The journey of Eteplirsen, Sarepta’s lead candidate for the treatment of DMD, is discussed from a technology platform perspective.

4) Plans are for a future meeting with the FDA about the chemistry, manufacturing, and controls (CMC)

***  5) 74-week Eteplirsen clinical trial data.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: